
BioNTech to wind down cell therapy manufacturing in Maryland, lay off 63 as it ends development of CAR-T drug in ...
Following a disappointing performance from the company’s CAR-T candidate in an early-stage cancer trial, BioNTech is winding down cell therapy manufacturing at its inaugural U.S. plant. BioNTech will lay off 63 employees at its Gaithersburg, Maryland, cell …